A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Active:	No
Cancer Type:	Bile Duct Cancer	NCT ID:	NCT03656536
Trial Phases:	Phase III	Protocol IDs:	INCB 54828-302 (primary) NCI-2019-01725
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Incyte Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT03656536

Summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus
gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with
unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.